APR 1 0 2002



CASE 4-30961

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV041586545 US Express Mail Label Number

April 10, 2002 Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1614

OKUNO ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP00/4562

FILED: 19 MAY 2000

U.S. APPLICATION NO: 09/989,577

35 USC §371 DATE: 20 NOVEMBER 2001

FOR: USE OF BISPHOSPHONIC ACIDS FOR TREATING

ANGIOGENESIS

RECEIVED

APR 1 5 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134, in the name of Novartis Corporation.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the International stage Search Report, a copy of which is enclosed herewith for the Convenience of the Examiner. Since these references are of record in the instant PCT application ,PCT/EP00/4562, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Corporation Patent and Trademark Dept. 564 Morris Avenue Summit, NJ 07901-1027 (908) 522-6932

Date: April 10, 2002

Attorney for Applicants Reg. No. 35,590

Carol A. Loeschorn